Innovations In In-Vitro Diagnostics: New Technologies, Growth Opportunities, And The Future Market Outlook

Published Date: June 2009 Published By: Business Insights Page Count: 134 Order Code: R162-964 $3,835.00   Online Download $14,381.25   Global Site License   Questions About This Report E-mail a Colleague Printable Page Fax Your Order Description Table of Contents Search Inside this Report Similar Products Innovations in In-Vitro Diagnostics Executive summary Overview Market analysis Coronary heart disease Heart failure Viral infectious Bacterial infections Market outlook Chapter 1 Overview Summary Introduction Classification of clinical diagnostics Market segments Clinical chemistry Immunoassays Estimated number of immunoassay analyzers by company Molecular diagnostics Point of care Pricing Regulation Increasing regulatory oversight Chapter 2 Market analysis Summary Introduction Sales by company Sales by market segment Acquisition activity Company profiles Roche Siemens Healthcare Diagnostics Abbott Ortho-Clinical Diagnostics Beckman Coulter Becton Dickinson Bio-Rad bioMérieux Inverness Medical Solutions Chapter 3 Coronary heart disease Summary Introduction Diagnosis of coronary heart disease Cardiac specific markers High-sensitive troponin assays Novel ultra-sensitive assays Potential clinical advances of novel assays Novel markers of coronary heart disease Cardiac ischemia Plaque instability Inflammation Future outlook Impact of novel troponin assays Incremental improvements Biomarkers for the early detection of disease Chapter 4 Heart failure Summary Introduction Diagnosis of heart failure Natriuretic peptides Novel markers of heart failure MR-proANP Soluble ST2 Troponin MR-proADM Future outlook Screening of asymptomatic patient populations Chapter 5 Viral infections Summary Introduction Blood screening Major companies in the blood screening market Blood screening market size Quantitative viral diagnostics Treatment of viral infections Respiratory viral panels Novel multiplex assays RSV in the elderly Future outlook Existing market growth Emerging markets Need for effective therapies Chapter 6 Bacterial infections Summary Introduction Sexually transmitted diseases Market size and key companies Healthcare associated infections Clostridium difficile Novel NAT based tests Market size for C.diff tests Methicillin-resistant Staphylococcus aureus Universal screening NAT based technologies Other rapid detection methods Universal screening market size Countries investing in MRSA screening Cost comparison of tests Future outlook Chapter 7 Market outlook Summary Introduction Trends in 510(k) approvals Barriers to innovation Immunoassays Factors driving testing volumes Molecular diagnostics Demonstration of clinical need Novel technologies Appendix Methodology Glossary List of Figures Figure 1.1: Estimated number of immunoassay analyzers sold since launch, by company, 2008 Figure 1.2: Existing and emerging markets for molecular diagnostics Figure 1.3: Cost of tests by technology and clinical application, 2009, US Figure 2.4: Clinical diagnostics sales, by company, 2008 Figure 2.5: Clinical diagnostic sales, by sector, 2008 Figure 3.6: Diagnosis of myocardial infarction Figure 3.7: High sensitive troponin assays, comparison of lower limit of detection Figure 3.8: Novel cardiac biomarkers Figure 3.9: Potential US market for diagnosis of coronary heart disease Figure 5.10: Deaths due to respiratory syncytial virus infection, by age, US, 2003 Figure 6.11: C. trachomatis and N. gonorrhoeae incidence rates, US, 1984-2007 Figure 6.12: Deaths due to CDAD as underlying cause of death, US, 1999-2006 Figure 6.13: CDAD infections in patients aged 65 years or older, England, 2006-2008 Figure 6.14: Cost breakdown of universal admission MRSA screening program Figure 6.15: Comparison of PCR and chromogenic media cost for universal admission MRSA screening program Figure 7.16: 510(k) approvals by medical specialty, 2006-2008 Figure 7.17: 510(k) approvals, 1997-2008 Figure 7.18: Number of Clinical Laboratory Fee Schedule Codes, 2003 and 2009 Figure 7.19: Hospital charges, by disease, 2006 Figure 7.20: Prevalence of self-reported cardiovascular disease by age, US List of Tables Table 1.1: Examples of commonly used in vivo and in vitro diagnostics Table 1.2: Number of clinical laboratories by type, US, 2008 Table 1.3: Estimated number and sales of immunoassay analyzers, by company, 2008 Table 2.4: Clinical diagnostics sales, by company, 2006-2008 Table 2.5: Acquisitions by company, 2007-2009 Table 2.6: Roche patenting activity Table 3.7: High sensitive troponin assays, comparison of lower limit of detection Similar Products • Testing Laboratories Published Nov 2009 by First Research, Inc. • Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads Published Nov 2009 by Kalorama Information • Infectious Disease Testing Market: US, Europe, Japan--Emerging Opportunities and Business Strategies Published Nov 2009 by Venture Planning Group • 2009 Worldwide Diagnostics Market Research Bundle Published Oct 2009 by Kalorama Information • Three Alternative Scenarios Of The Future In Vitro Diagnostics Market 2009-2018 Published Oct 2009 by Venture Planning Group • Preventive Healthcare Technologies, Products and Markets Published Oct 2009 by BCC Research • The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets Published Oct 2009 by Kalorama Information • Veterinary Diagnostics Markets Published Oct 2009 by Kalorama Information • Innovations in Oncology Diagnostics: Technological advances, growth opportunities and future market outlook Published Oct 2009 by Business Insights